News

Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry’s decline of 2.2%. The ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...
Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...
Wells Fargo said the U.S. Supreme Court’s decision to preserve no-cost coverage for preventive services marks a “win for ...
As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...
What kind of uptake can Gilead Sciences expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) ...
The US Food and Drug Administration (FDA) has approved Gilead Science’s Yeztugo for the prevention of human immunodeficiency ...
Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...
The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking studies, Gilead Sciences’ shot, a drug named lenacapavir, nearly eliminated new ...
The Benzinga Stock Whisper Index highlights five stocks that saw increased interest from readers during the week and a look ...
Labcorp (LH), and Gilead (GILD) rise as Supreme Court upholds right to free preventive care under Obamacare. Read more here.